The Experts below are selected from a list of 22800 Experts worldwide ranked by ideXlab platform

Einar K Rofstad - One of the best experts on this subject based on the ideXlab platform.

  • inactivation of human osteosarcoma cells in vitro by 211at tp 3 monoclonal antibody comparison with astatine 211 labeled bovine serum albumin free astatine 211 and external beam x rays
    Radiation Research, 1994
    Co-Authors: Roy H. Larsen, Oyvind S Bruland, Per Hoff, Jorolf Alstad, Tore Lindmo, Einar K Rofstad
    Abstract:

    The potential usefulness of {alpha}-particle radioimmunotherapy in the treatment of osteosarcoma was studied in vitro by using the monoclonal antibody TP-3 and cells of three human osteosarcoma cell lines (OHS, SAOS and KPDX) differing in antigen expression. Cell survival curves were established after treatment with (a) {sup 211}At-TP-3 of different specific activities, (b) {sup 211}At-labeled bovine serum albumin (BSA), (c) free {sup 211}At and (d) external-beam X rays. The three osteosarcoma cell lines showed similar survival curves, whether treated with external-beam X rays, {sup 211}At-BSA or free {sup 211}At. The D{sub o}`s were lower for free {sup 211}At than for {sup 211}At-BSA. The survival curves for {sup 211}At-TP-3 treatment, on the other hand, differed significantly among the cell lines, suggesting that sensitivity to {sup 211}At-TP-3 treatment was governed by Cellular properties other than sensitivity to external-beam X rays. The Cellular Property most important for sensitivity to {sup 211}At-TP-3 treatment was the antigen expression. Cell inactivation after {sup 211}At-TP-3 treatment increased substantially with increasing specific activity of the {sup 211}At-TP-3. At high specific activities, the cytotoxic effect of {sup 211}At-TP-3 was significantly higher than that of {sup 211}At-BSA. In conclusion, {sup 211}At-TP-3 has the potential to give clinically favorable therapeutic ratiosmore » in the treatment of osteosarcoma. 39 refs., 5 figs., 2 tabs.« less

  • inactivation of human osteosarcoma cells in vitro by 211at tp 3 monoclonal antibody comparison with astatine 211 labeled bovine serum albumin free astatine 211 and external beam x rays
    Radiation Research, 1994
    Co-Authors: Roy H. Larsen, Oyvind S Bruland, Per Hoff, Jorolf Alstad, Tore Lindmo, Einar K Rofstad
    Abstract:

    The potential usefulness of alpha-particle radioimmunotherapy in the treatment of osteosarcoma was studied in vitro by using the monoclonal antibody TP-3 and cells of three human osteosarcoma cell lines (OHS, SAOS and KPDX) differing in antigen expression. Cell survival curves were established after treatment with (a) 211At-TP-3 of different specific activities, (b) 211At-labeled bovine serum albumin (BSA), (c) free 211At and (d) external-beam X rays. The three osteosarcoma cell lines showed similar survival curves, whether treated with external-beam X rays, 211At-BSA or free 211At. The D0's were lower for free 211At than for 211At-BSA. The survival curves for 211At-TP-3 treatment, on the other hand, differed significantly among the cell lines, suggesting that sensitivity to 211At-TP-3 treatment was governed by Cellular properties other than sensitivity to external-beam X rays. The Cellular Property most important for sensitivity to 211At-TP-3 treatment was the antigen expression. Cell inactivation after 211At-TP-3 treatment increased substantially with increasing specific activity of the 211At-TP-3. At high specific activities, the cytotoxic effect of 211At-TP-3 was significantly higher than that of 211At-BSA. In conclusion, 211At-TP-3 has the potential to give clinically favorable therapeutic ratios in the treatment of osteosarcoma.

Roy H. Larsen - One of the best experts on this subject based on the ideXlab platform.

  • inactivation of human osteosarcoma cells in vitro by 211at tp 3 monoclonal antibody comparison with astatine 211 labeled bovine serum albumin free astatine 211 and external beam x rays
    Radiation Research, 1994
    Co-Authors: Roy H. Larsen, Oyvind S Bruland, Per Hoff, Jorolf Alstad, Tore Lindmo, Einar K Rofstad
    Abstract:

    The potential usefulness of {alpha}-particle radioimmunotherapy in the treatment of osteosarcoma was studied in vitro by using the monoclonal antibody TP-3 and cells of three human osteosarcoma cell lines (OHS, SAOS and KPDX) differing in antigen expression. Cell survival curves were established after treatment with (a) {sup 211}At-TP-3 of different specific activities, (b) {sup 211}At-labeled bovine serum albumin (BSA), (c) free {sup 211}At and (d) external-beam X rays. The three osteosarcoma cell lines showed similar survival curves, whether treated with external-beam X rays, {sup 211}At-BSA or free {sup 211}At. The D{sub o}`s were lower for free {sup 211}At than for {sup 211}At-BSA. The survival curves for {sup 211}At-TP-3 treatment, on the other hand, differed significantly among the cell lines, suggesting that sensitivity to {sup 211}At-TP-3 treatment was governed by Cellular properties other than sensitivity to external-beam X rays. The Cellular Property most important for sensitivity to {sup 211}At-TP-3 treatment was the antigen expression. Cell inactivation after {sup 211}At-TP-3 treatment increased substantially with increasing specific activity of the {sup 211}At-TP-3. At high specific activities, the cytotoxic effect of {sup 211}At-TP-3 was significantly higher than that of {sup 211}At-BSA. In conclusion, {sup 211}At-TP-3 has the potential to give clinically favorable therapeutic ratiosmore » in the treatment of osteosarcoma. 39 refs., 5 figs., 2 tabs.« less

  • inactivation of human osteosarcoma cells in vitro by 211at tp 3 monoclonal antibody comparison with astatine 211 labeled bovine serum albumin free astatine 211 and external beam x rays
    Radiation Research, 1994
    Co-Authors: Roy H. Larsen, Oyvind S Bruland, Per Hoff, Jorolf Alstad, Tore Lindmo, Einar K Rofstad
    Abstract:

    The potential usefulness of alpha-particle radioimmunotherapy in the treatment of osteosarcoma was studied in vitro by using the monoclonal antibody TP-3 and cells of three human osteosarcoma cell lines (OHS, SAOS and KPDX) differing in antigen expression. Cell survival curves were established after treatment with (a) 211At-TP-3 of different specific activities, (b) 211At-labeled bovine serum albumin (BSA), (c) free 211At and (d) external-beam X rays. The three osteosarcoma cell lines showed similar survival curves, whether treated with external-beam X rays, 211At-BSA or free 211At. The D0's were lower for free 211At than for 211At-BSA. The survival curves for 211At-TP-3 treatment, on the other hand, differed significantly among the cell lines, suggesting that sensitivity to 211At-TP-3 treatment was governed by Cellular properties other than sensitivity to external-beam X rays. The Cellular Property most important for sensitivity to 211At-TP-3 treatment was the antigen expression. Cell inactivation after 211At-TP-3 treatment increased substantially with increasing specific activity of the 211At-TP-3. At high specific activities, the cytotoxic effect of 211At-TP-3 was significantly higher than that of 211At-BSA. In conclusion, 211At-TP-3 has the potential to give clinically favorable therapeutic ratios in the treatment of osteosarcoma.

Tore Lindmo - One of the best experts on this subject based on the ideXlab platform.

  • inactivation of human osteosarcoma cells in vitro by 211at tp 3 monoclonal antibody comparison with astatine 211 labeled bovine serum albumin free astatine 211 and external beam x rays
    Radiation Research, 1994
    Co-Authors: Roy H. Larsen, Oyvind S Bruland, Per Hoff, Jorolf Alstad, Tore Lindmo, Einar K Rofstad
    Abstract:

    The potential usefulness of {alpha}-particle radioimmunotherapy in the treatment of osteosarcoma was studied in vitro by using the monoclonal antibody TP-3 and cells of three human osteosarcoma cell lines (OHS, SAOS and KPDX) differing in antigen expression. Cell survival curves were established after treatment with (a) {sup 211}At-TP-3 of different specific activities, (b) {sup 211}At-labeled bovine serum albumin (BSA), (c) free {sup 211}At and (d) external-beam X rays. The three osteosarcoma cell lines showed similar survival curves, whether treated with external-beam X rays, {sup 211}At-BSA or free {sup 211}At. The D{sub o}`s were lower for free {sup 211}At than for {sup 211}At-BSA. The survival curves for {sup 211}At-TP-3 treatment, on the other hand, differed significantly among the cell lines, suggesting that sensitivity to {sup 211}At-TP-3 treatment was governed by Cellular properties other than sensitivity to external-beam X rays. The Cellular Property most important for sensitivity to {sup 211}At-TP-3 treatment was the antigen expression. Cell inactivation after {sup 211}At-TP-3 treatment increased substantially with increasing specific activity of the {sup 211}At-TP-3. At high specific activities, the cytotoxic effect of {sup 211}At-TP-3 was significantly higher than that of {sup 211}At-BSA. In conclusion, {sup 211}At-TP-3 has the potential to give clinically favorable therapeutic ratiosmore » in the treatment of osteosarcoma. 39 refs., 5 figs., 2 tabs.« less

  • inactivation of human osteosarcoma cells in vitro by 211at tp 3 monoclonal antibody comparison with astatine 211 labeled bovine serum albumin free astatine 211 and external beam x rays
    Radiation Research, 1994
    Co-Authors: Roy H. Larsen, Oyvind S Bruland, Per Hoff, Jorolf Alstad, Tore Lindmo, Einar K Rofstad
    Abstract:

    The potential usefulness of alpha-particle radioimmunotherapy in the treatment of osteosarcoma was studied in vitro by using the monoclonal antibody TP-3 and cells of three human osteosarcoma cell lines (OHS, SAOS and KPDX) differing in antigen expression. Cell survival curves were established after treatment with (a) 211At-TP-3 of different specific activities, (b) 211At-labeled bovine serum albumin (BSA), (c) free 211At and (d) external-beam X rays. The three osteosarcoma cell lines showed similar survival curves, whether treated with external-beam X rays, 211At-BSA or free 211At. The D0's were lower for free 211At than for 211At-BSA. The survival curves for 211At-TP-3 treatment, on the other hand, differed significantly among the cell lines, suggesting that sensitivity to 211At-TP-3 treatment was governed by Cellular properties other than sensitivity to external-beam X rays. The Cellular Property most important for sensitivity to 211At-TP-3 treatment was the antigen expression. Cell inactivation after 211At-TP-3 treatment increased substantially with increasing specific activity of the 211At-TP-3. At high specific activities, the cytotoxic effect of 211At-TP-3 was significantly higher than that of 211At-BSA. In conclusion, 211At-TP-3 has the potential to give clinically favorable therapeutic ratios in the treatment of osteosarcoma.

Oyvind S Bruland - One of the best experts on this subject based on the ideXlab platform.

  • inactivation of human osteosarcoma cells in vitro by 211at tp 3 monoclonal antibody comparison with astatine 211 labeled bovine serum albumin free astatine 211 and external beam x rays
    Radiation Research, 1994
    Co-Authors: Roy H. Larsen, Oyvind S Bruland, Per Hoff, Jorolf Alstad, Tore Lindmo, Einar K Rofstad
    Abstract:

    The potential usefulness of {alpha}-particle radioimmunotherapy in the treatment of osteosarcoma was studied in vitro by using the monoclonal antibody TP-3 and cells of three human osteosarcoma cell lines (OHS, SAOS and KPDX) differing in antigen expression. Cell survival curves were established after treatment with (a) {sup 211}At-TP-3 of different specific activities, (b) {sup 211}At-labeled bovine serum albumin (BSA), (c) free {sup 211}At and (d) external-beam X rays. The three osteosarcoma cell lines showed similar survival curves, whether treated with external-beam X rays, {sup 211}At-BSA or free {sup 211}At. The D{sub o}`s were lower for free {sup 211}At than for {sup 211}At-BSA. The survival curves for {sup 211}At-TP-3 treatment, on the other hand, differed significantly among the cell lines, suggesting that sensitivity to {sup 211}At-TP-3 treatment was governed by Cellular properties other than sensitivity to external-beam X rays. The Cellular Property most important for sensitivity to {sup 211}At-TP-3 treatment was the antigen expression. Cell inactivation after {sup 211}At-TP-3 treatment increased substantially with increasing specific activity of the {sup 211}At-TP-3. At high specific activities, the cytotoxic effect of {sup 211}At-TP-3 was significantly higher than that of {sup 211}At-BSA. In conclusion, {sup 211}At-TP-3 has the potential to give clinically favorable therapeutic ratiosmore » in the treatment of osteosarcoma. 39 refs., 5 figs., 2 tabs.« less

  • inactivation of human osteosarcoma cells in vitro by 211at tp 3 monoclonal antibody comparison with astatine 211 labeled bovine serum albumin free astatine 211 and external beam x rays
    Radiation Research, 1994
    Co-Authors: Roy H. Larsen, Oyvind S Bruland, Per Hoff, Jorolf Alstad, Tore Lindmo, Einar K Rofstad
    Abstract:

    The potential usefulness of alpha-particle radioimmunotherapy in the treatment of osteosarcoma was studied in vitro by using the monoclonal antibody TP-3 and cells of three human osteosarcoma cell lines (OHS, SAOS and KPDX) differing in antigen expression. Cell survival curves were established after treatment with (a) 211At-TP-3 of different specific activities, (b) 211At-labeled bovine serum albumin (BSA), (c) free 211At and (d) external-beam X rays. The three osteosarcoma cell lines showed similar survival curves, whether treated with external-beam X rays, 211At-BSA or free 211At. The D0's were lower for free 211At than for 211At-BSA. The survival curves for 211At-TP-3 treatment, on the other hand, differed significantly among the cell lines, suggesting that sensitivity to 211At-TP-3 treatment was governed by Cellular properties other than sensitivity to external-beam X rays. The Cellular Property most important for sensitivity to 211At-TP-3 treatment was the antigen expression. Cell inactivation after 211At-TP-3 treatment increased substantially with increasing specific activity of the 211At-TP-3. At high specific activities, the cytotoxic effect of 211At-TP-3 was significantly higher than that of 211At-BSA. In conclusion, 211At-TP-3 has the potential to give clinically favorable therapeutic ratios in the treatment of osteosarcoma.

Per Hoff - One of the best experts on this subject based on the ideXlab platform.

  • inactivation of human osteosarcoma cells in vitro by 211at tp 3 monoclonal antibody comparison with astatine 211 labeled bovine serum albumin free astatine 211 and external beam x rays
    Radiation Research, 1994
    Co-Authors: Roy H. Larsen, Oyvind S Bruland, Per Hoff, Jorolf Alstad, Tore Lindmo, Einar K Rofstad
    Abstract:

    The potential usefulness of {alpha}-particle radioimmunotherapy in the treatment of osteosarcoma was studied in vitro by using the monoclonal antibody TP-3 and cells of three human osteosarcoma cell lines (OHS, SAOS and KPDX) differing in antigen expression. Cell survival curves were established after treatment with (a) {sup 211}At-TP-3 of different specific activities, (b) {sup 211}At-labeled bovine serum albumin (BSA), (c) free {sup 211}At and (d) external-beam X rays. The three osteosarcoma cell lines showed similar survival curves, whether treated with external-beam X rays, {sup 211}At-BSA or free {sup 211}At. The D{sub o}`s were lower for free {sup 211}At than for {sup 211}At-BSA. The survival curves for {sup 211}At-TP-3 treatment, on the other hand, differed significantly among the cell lines, suggesting that sensitivity to {sup 211}At-TP-3 treatment was governed by Cellular properties other than sensitivity to external-beam X rays. The Cellular Property most important for sensitivity to {sup 211}At-TP-3 treatment was the antigen expression. Cell inactivation after {sup 211}At-TP-3 treatment increased substantially with increasing specific activity of the {sup 211}At-TP-3. At high specific activities, the cytotoxic effect of {sup 211}At-TP-3 was significantly higher than that of {sup 211}At-BSA. In conclusion, {sup 211}At-TP-3 has the potential to give clinically favorable therapeutic ratiosmore » in the treatment of osteosarcoma. 39 refs., 5 figs., 2 tabs.« less

  • inactivation of human osteosarcoma cells in vitro by 211at tp 3 monoclonal antibody comparison with astatine 211 labeled bovine serum albumin free astatine 211 and external beam x rays
    Radiation Research, 1994
    Co-Authors: Roy H. Larsen, Oyvind S Bruland, Per Hoff, Jorolf Alstad, Tore Lindmo, Einar K Rofstad
    Abstract:

    The potential usefulness of alpha-particle radioimmunotherapy in the treatment of osteosarcoma was studied in vitro by using the monoclonal antibody TP-3 and cells of three human osteosarcoma cell lines (OHS, SAOS and KPDX) differing in antigen expression. Cell survival curves were established after treatment with (a) 211At-TP-3 of different specific activities, (b) 211At-labeled bovine serum albumin (BSA), (c) free 211At and (d) external-beam X rays. The three osteosarcoma cell lines showed similar survival curves, whether treated with external-beam X rays, 211At-BSA or free 211At. The D0's were lower for free 211At than for 211At-BSA. The survival curves for 211At-TP-3 treatment, on the other hand, differed significantly among the cell lines, suggesting that sensitivity to 211At-TP-3 treatment was governed by Cellular properties other than sensitivity to external-beam X rays. The Cellular Property most important for sensitivity to 211At-TP-3 treatment was the antigen expression. Cell inactivation after 211At-TP-3 treatment increased substantially with increasing specific activity of the 211At-TP-3. At high specific activities, the cytotoxic effect of 211At-TP-3 was significantly higher than that of 211At-BSA. In conclusion, 211At-TP-3 has the potential to give clinically favorable therapeutic ratios in the treatment of osteosarcoma.